TY - JOUR
T1 - How should hypomagnesaemia be investigated and treated?
AU - Ayuk, John
AU - Gittoes, Neil
PY - 2011/12/1
Y1 - 2011/12/1
N2 - Hypomagnesaemia is relatively common, with an estimated prevalence in the general population ranging from 2·5% to 15%. It may result from inadequate magnesium intake, increased gastrointestinal or renal loss or redistribution from extracellular to intracellular space. Drug-induced hypomagnesaemia, particularly related to proton pump inhibitor (PPI) therapy, is being increasingly recognized. Most patients with hypomagnesaemia are asymptomatic; symptomatic magnesium depletion is often associated with multiple other biochemical abnormalities, including hypokalaemia, hypocalcaemia and metabolic acidosis. Manifestations of symptomatic hypomagnesaemia most often involve neuromuscular, cardiovascular and metabolic features. Patients with symptomatic hypomagnesaemia should be treated with intravenous magnesium, reserving oral replacement for asymptomatic patients.
AB - Hypomagnesaemia is relatively common, with an estimated prevalence in the general population ranging from 2·5% to 15%. It may result from inadequate magnesium intake, increased gastrointestinal or renal loss or redistribution from extracellular to intracellular space. Drug-induced hypomagnesaemia, particularly related to proton pump inhibitor (PPI) therapy, is being increasingly recognized. Most patients with hypomagnesaemia are asymptomatic; symptomatic magnesium depletion is often associated with multiple other biochemical abnormalities, including hypokalaemia, hypocalcaemia and metabolic acidosis. Manifestations of symptomatic hypomagnesaemia most often involve neuromuscular, cardiovascular and metabolic features. Patients with symptomatic hypomagnesaemia should be treated with intravenous magnesium, reserving oral replacement for asymptomatic patients.
U2 - 10.1111/j.1365-2265.2011.04092.x
DO - 10.1111/j.1365-2265.2011.04092.x
M3 - Article
C2 - 21569071
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
SN - 1365-2265
VL - 75
SP - 743
EP - 746
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 6
ER -